Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kairos Pharma (KAPA) EBITDA (2024 - 2025)

Kairos Pharma (KAPA) has disclosed EBITDA for 2 consecutive years, with -$1.5 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA fell 555.86% year-over-year to -$1.5 million, compared with a TTM value of -$4.6 million through Jun 2025, changed N/A, and an annual FY2024 reading of -$2.3 million, down 36.7% over the prior year.
  • EBITDA was -$1.5 million for Q2 2025 at Kairos Pharma, down from -$1.3 million in the prior quarter.
  • Across five years, EBITDA topped out at -$222000.0 in Q2 2024 and bottomed at -$1.5 million in Q2 2025.